Tumor-Secreted Protein May Hold the Key to Better Treatments for Deadly Brain Tumor Jan. 8, 2025 — A study has found targeting a protein called endocan and its related signaling pathway could be ...

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. Patents protecting ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Merck’s mega blockbuster Keytruda paired with Eisai’s Lenvima did not improve overall survival in a Phase III clinical trial of patients with an advanced form of gastroesophageal adenocarcinoma. While ...

The com­bi­na­tion of Mer­ck’s Keytru­da and Ei­sai’s Lenvi­ma failed to pro­long pa­tients’ lives ver­sus the com­para­tor in an­oth­er can­cer study, but the com­pa­nies ...

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, ...

The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME ... from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on ...